









市场行情
/
股票
/
nasdaq-svra
/

Savara Inc

SVRA

6.450USD

+0.050+0.78%

收盘 12/26, 16:00（美东）报价延迟15分钟

1.11B总市值

亏损市盈率 TTM



Savara Inc

6.450

+0.050+0.78%

概览公司财务分析

概览

公司

财务

分析

关于 Savara Inc 公司

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Savara Inc简介



公司代码SVRA

公司名称Savara Inc

上市日期Jun 25, 2001

CEOPauls (Matthew)

员工数量59

证券类型Ordinary Share

年结日Jun 25

公司地址6836 Bee Cave Road

城市AUSTIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编78746

电话151285113796

网址https://savarapharma.com/

公司代码SVRA

上市日期Jun 25, 2001

CEOPauls (Matthew)

Savara Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

Mr. Richard J. (Rick) Hawkins

Independent Director

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

Dr. Raymond Dennis (Ray) Pratt, M.D.

Chief Medical Officer

名称

名称/职务

职务

持股

持股变动

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

New Enterprise Associates (NEA)

12.03%

Bain Capital Life Sciences Investors, LLC

8.65%

Deerfield Management Company, L.P.

6.67%

VR Adviser, LLC

6.23%

TCG Crossover Management, LLC

6.08%

其他

60.35%

持股股东

占比

New Enterprise Associates (NEA)

12.03%

Bain Capital Life Sciences Investors, LLC

8.65%

Deerfield Management Company, L.P.

6.67%

VR Adviser, LLC

6.23%

TCG Crossover Management, LLC

6.08%

其他

60.35%

股东类型

持股股东

占比

Investment Advisor

28.82%

Venture Capital

19.47%

Hedge Fund

18.75%

Investment Advisor/Hedge Fund

9.69%

Private Equity

5.63%

Individual Investor

2.15%

Research Firm

1.54%

Bank and Trust

0.11%

Insurance Company

0.02%

其他

13.80%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

286

169.85M

86.94%

-21.45M

2025Q2

295

181.81M

105.19%

-8.48M

2025Q1

306

176.74M

102.29%

-9.64M

2024Q4

294

173.80M

101.27%

-5.45M

2024Q3

274

169.68M

103.28%

+3.87M

2024Q2

257

157.29M

95.89%

+28.15M

2024Q1

230

131.01M

94.21%

-92.17K

2023Q4

197

123.19M

91.03%

-2.15M

2023Q3

177

120.11M

89.27%

+14.67M

2023Q2

170

92.45M

81.05%

-2.68M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

New Enterprise Associates (NEA)

24.47M

14.16%

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

17.60M

10.18%

Jun 30, 2025

Deerfield Management Company, L.P.

7.96M

4.61%

Jun 30, 2025

VR Adviser, LLC

8.88M

5.14%

+5.63M

+172.72%

Jun 30, 2025

TCG Crossover Management, LLC

12.36M

7.15%

Jun 30, 2025

Frazier Life Sciences Management, L.P.

11.46M

6.63%

Jun 30, 2025

Nantahala Capital Management, LLC

8.33M

4.82%

+250.00K

+3.10%

Jun 30, 2025

The Vanguard Group, Inc.

8.43M

4.88%

+334.73K

+4.13%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.54M

4.94%

-164.33K

-1.89%

Jun 30, 2025

Emerald Advisers LLC

5.72M

3.31%

+616.10K

+12.07%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

1.24%

Texas Capital Texas Small Cap Equity Index ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.13%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.07%

Texas Capital Texas Equity Index ETF

0.05%

iShares Biotechnology ETF

0.03%

ProShares Hedge Replication ETF

0.03%

Invesco RAFI US 1500 Small-Mid ETF

0.03%

iShares Russell 2000 Growth ETF

0.03%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.24%

Texas Capital Texas Small Cap Equity Index ETF

占比0.24%

ProShares Ultra Nasdaq Biotechnology

占比0.13%

iShares Micro-Cap ETF

占比0.09%

Invesco Nasdaq Biotechnology ETF

占比0.07%

Texas Capital Texas Equity Index ETF

占比0.05%

iShares Biotechnology ETF

占比0.03%

ProShares Hedge Replication ETF

占比0.03%

Invesco RAFI US 1500 Small-Mid ETF

占比0.03%

iShares Russell 2000 Growth ETF

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Savara Inc的前五大股东是谁？



Savara Inc 的前五大股东如下：
New Enterprise Associates (NEA)持有股份：24.47M，占总股份比例：14.16%。
Bain Capital Life Sciences Investors, LLC持有股份：17.60M，占总股份比例：10.18%。
Deerfield Management Company, L.P.持有股份：7.96M，占总股份比例：4.61%。
VR Adviser, LLC持有股份：8.88M，占总股份比例：5.14%。
TCG Crossover Management, LLC持有股份：12.36M，占总股份比例：7.15%。